4D Molecular Therapeutics, Inc. (FDMT) Balance Sheet
As of 2026-06-30 (10-Q), 4D Molecular Therapeutics, Inc. (FDMT) reported total assets of $492.6M, total liabilities of $85.0M and shareholders' equity of $407.7M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $70.4M. Long-term debt: $19.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free
—
Price chart with a free account
- Market cap
- 779.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 49.7 | 276.7 | 153.0 | 52.4 | 249.1 | 149.3 | 60.2 | 70.4 | |
| Short-term investments | — | 0.0 | 94.8 | 161.2 | 39.1 | 275.5 | 342.4 | 291.0 | |
| Receivables | 1.0 | 1.5 | 0.0 | 0.0 | — | — | — | — | |
| Current assets | 52.5 | 282.7 | 256.3 | 220.5 | 296.6 | 434.9 | 413.1 | 383.0 | |
| Total assets | 58.2 | 288.3 | 353.5 | 261.8 | 339.9 | 560.4 | 566.7 | 492.6 | |
| Current liabilities | 13.0 | 16.7 | 16.3 | 15.7 | 19.0 | 29.1 | 44.0 | 47.7 | |
| Long-term debt | — | — | — | — | — | — | 0.0 | 19.6 | |
| Total liabilities | 28.2 | 31.9 | 34.4 | 30.5 | 32.1 | 49.8 | 61.0 | 85.0 | |
| Shareholders' equity | -73.0 | 256.4 | 319.1 | 231.3 | 307.8 | 510.6 | 505.7 | 407.7 |
USD millions · SEC XBRL
4D Molecular Therapeutics, Inc. — questions
- How much cash does 4D Molecular Therapeutics, Inc. have?
- $70.4M in cash and cash equivalents as of 2026-06-30.
- How much debt does 4D Molecular Therapeutics, Inc. have?
- $19.6M of long-term debt as of 2026-06-30.
- What are 4D Molecular Therapeutics, Inc.'s total assets?
- $492.6M as of 2026-06-30.
- What is 4D Molecular Therapeutics, Inc.'s shareholders' equity?
- $407.7M as of 2026-06-30.
Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.